These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 19467306)

  • 1. Drug development in oncology assisted by noninvasive optical imaging.
    Sancey L; Dufort S; Josserand V; Keramidas M; Righini C; Rome C; Faure AC; Foillard S; Roux S; Boturyn D; Tillement O; Koenig A; Boutet J; Rizo P; Dumy P; Coll JL
    Int J Pharm; 2009 Sep; 379(2):309-16. PubMed ID: 19467306
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multifunctional nanoparticles for imaging, delivery and targeting in cancer therapy.
    Gindy ME; Prud'homme RK
    Expert Opin Drug Deliv; 2009 Aug; 6(8):865-78. PubMed ID: 19637974
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Newly developed strategies for multifunctional mitochondria-targeted agents in cancer therapy.
    Zhang E; Zhang C; Su Y; Cheng T; Shi C
    Drug Discov Today; 2011 Feb; 16(3-4):140-6. PubMed ID: 21182981
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High contrast upconversion luminescence targeted imaging in vivo using peptide-labeled nanophosphors.
    Xiong L; Chen Z; Tian Q; Cao T; Xu C; Li F
    Anal Chem; 2009 Nov; 81(21):8687-94. PubMed ID: 19817386
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optical imaging in oncology.
    Kim HL
    Urol Oncol; 2009; 27(3):298-300. PubMed ID: 19414116
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Live cell imaging for target and drug discovery.
    Watson P
    Drug News Perspect; 2009 Mar; 22(2):69-79. PubMed ID: 19330166
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Active targeting schemes for nanoparticle systems in cancer therapeutics.
    Byrne JD; Betancourt T; Brannon-Peppas L
    Adv Drug Deliv Rev; 2008 Dec; 60(15):1615-26. PubMed ID: 18840489
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biofunctionalized, phosphonate-grafted, ultrasmall iron oxide nanoparticles for combined targeted cancer therapy and multimodal imaging.
    Das M; Mishra D; Dhak P; Gupta S; Maiti TK; Basak A; Pramanik P
    Small; 2009 Dec; 5(24):2883-93. PubMed ID: 19856326
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Noninvasive structural, functional, and molecular imaging in drug development.
    Rudin M
    Curr Opin Chem Biol; 2009 Jun; 13(3):360-71. PubMed ID: 19447067
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Receptor-targeted optical imaging of tumors with near-infrared fluorescent ligands.
    Becker A; Hessenius C; Licha K; Ebert B; Sukowski U; Semmler W; Wiedenmann B; Grötzinger C
    Nat Biotechnol; 2001 Apr; 19(4):327-31. PubMed ID: 11283589
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nanoshell-enabled photothermal cancer therapy: impending clinical impact.
    Lal S; Clare SE; Halas NJ
    Acc Chem Res; 2008 Dec; 41(12):1842-51. PubMed ID: 19053240
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dermatan carriers for neovascular transport targeting, deep tumor penetration and improved therapy.
    Ranney D; Antich P; Dadey E; Mason R; Kulkarni P; Singh O; Chen H; Constantanescu A; Parkey R
    J Control Release; 2005 Dec; 109(1-3):222-35. PubMed ID: 16290245
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery and development of folic-acid-based receptor targeting for imaging and therapy of cancer and inflammatory diseases.
    Low PS; Henne WA; Doorneweerd DD
    Acc Chem Res; 2008 Jan; 41(1):120-9. PubMed ID: 17655275
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Towards the use of nanoparticles in cancer therapy and imaging.
    Pauwels EK; Erba P
    Drug News Perspect; 2007 May; 20(4):213-20. PubMed ID: 17637933
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optical antisense imaging of tumor with fluorescent DNA duplexes.
    Liu X; Wang Y; Nakamura K; Liu G; Dou S; Kubo A; Rusckowski M; Hnatowich DJ
    Bioconjug Chem; 2007; 18(6):1905-11. PubMed ID: 17939728
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nonviral nanoscale-based delivery of antisense oligonucleotides targeted to hypoxia-inducible factor 1 alpha enhances the efficacy of chemotherapy in drug-resistant tumor.
    Wang Y; Saad M; Pakunlu RI; Khandare JJ; Garbuzenko OB; Vetcher AA; Soldatenkov VA; Pozharov VP; Minko T
    Clin Cancer Res; 2008 Jun; 14(11):3607-16. PubMed ID: 18519795
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New science-based endpoints to accelerate oncology drug development.
    Kelloff GJ; Sigman CC
    Eur J Cancer; 2005 Mar; 41(4):491-501. PubMed ID: 15737552
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Liposomal cancer therapy: exploiting tumor characteristics.
    Kaasgaard T; Andresen TL
    Expert Opin Drug Deliv; 2010 Feb; 7(2):225-43. PubMed ID: 20095944
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pathogenesis of metastatic disease: implications for current therapy and for the development of new therapeutic strategies.
    Poste G
    Cancer Treat Rep; 1986 Jan; 70(1):183-99. PubMed ID: 3510734
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.